GSK buys exclusive rights from Syndivia for ADC in prostate cancer
(Alliance News) - GSK PLC on Monday announced an agreement with Syndivia that grants GSK exclusive worldwide rights to develop and commercialise a preclinical antibody-drug conjugate for metastatic castration-resistant prostate cancer. Read More